← Eichor
Condition: Surufatinib Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Surufatinib

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07609121A Clinical Study of Surufatinib Combined With Chemotherapy as Neoadjuvant Treatment in Osteosarcoma
Phase 2 · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT05926492Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
Phase 4 · 4 location(s) · Shanghai Zhongshan Hospital · NCT07272512Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)
Phase 2 · 2 location(s) · Peking University · NCT05165407Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Ri
Phase 3 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT07436741Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unres
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07086469Surufatinib Combined With Chemo Versus Surufatinib in the Treatment of Pulmonary Neuroendocrine Tumors
Phase 2 · 4 location(s) · Shanghai Chest Hospital · NCT07357623The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue Sarcoma
Phase 1/Phase 2 · 1 location(s) · Fudan University · NCT05839275Surufatinib Combined with Envolizumab As Second-line Treatment for Recurrent/Metastatic HNSCC
Phase 2 · 1 location(s) · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao · NCT06876844Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Smal
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07086456A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and
Phase 2/Phase 3 · 2 location(s) · Hutchmed · NCT06361888A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.
Phase 1/Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT05747729A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Loca
Phase 2 · 1 location(s) · Fudan University · NCT05969171Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05989425Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in t
Phase 2 · 1 location(s) · Dai, Guanghai · NCT06708858An Open, Single-center Clinical Study of Surufatinib Combined With Temozolomide and S-1 in the First-line Treatment of A
Phase 1/Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06038461Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Th
Phase 2 · 1 location(s) · Anhui Provincial Cancer Hospital · NCT06437353Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06719700Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
Phase 1/Phase 2 · 1 location(s) · Chinese PLA General Hospital · NCT05218889Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT05472948Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Wit
Phase 2/Phase 3 · 1 location(s) · The First Hospital of Jilin University · NCT07505472
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.